MedTrace Logo

Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation

NCT00186420 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2012-06-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate time to progression (TTP) by PSA in patients with high risk prostate cancer after definitive therapy.

Conditions

Interventions

DRUG

Taxotere

Sponsors & Collaborators

Principal Investigators

  • Sandy Srinivas, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2006-01-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186420 on ClinicalTrials.gov